The Relationship Between Antipsychotic Treatment and Plasma β-Endorphin Concentration in Patients with Schizophrenia

Código QR

The Relationship Between Antipsychotic Treatment and Plasma β-Endorphin Concentration in Patients with Schizophrenia

Małgorzata Urban-Kowalczyk,1 Magdalena Kotlicka-Antczak,1 Dominik Strzelecki,1 Ewa Rudecka,2 Janusz Śmigielski3 1Department of Affective and Psychotic Disorders, Medical University of Lodz, Lodz, Poland; 2Faculty of Human Nutrition and Consumer Sciences, Warsaw University of Life Sciences SGGW, Wars...

Descripción completa

Guardado en:

Detalles Bibliográficos
Autores principales:	Urban-Kowalczyk M, Kotlicka-Antczak M, Strzelecki D, Rudecka E, Śmigielski J
Formato:	article
Lenguaje:	EN
Publicado:	Dove Medical Press 2021
Materias:	negative symptoms endogenous opioids schizophrenia psychosis Neurosciences. Biological psychiatry. Neuropsychiatry RC321-571 Neurology. Diseases of the nervous system RC346-429
Acceso en línea:	https://doaj.org/article/1c0a9627fdbd48e6972bd4a02fdbd91c
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!

Ejemplares similares

Odor perception and hedonics in chronic schizophrenia and in first episode psychosis
por: Urban-Kowalczyk M, et al.
Publicado: (2019)

The Relationship Between Course of Illness and β-Endorphin Plasma Levels in Patients with Schizophrenia
por: Urban-Kowalczyk M, et al.
Publicado: (2020)

Comparison of beta-endorphin and CGRP levels before and after treatment for severe schizophrenia
por: Urban-Kowalczyk M, et al.
Publicado: (2016)

Cariprazine: Patients with Treatment-Resistant Schizophrenia
por: Aubel T
Publicado: (2021)

Elevated activity of superoxide dismutase in male late-life schizophrenia and its correlation with clinical symptoms and cognitive deficits
por: Lijuan Huo, et al.
Publicado: (2021)

Aberrant Learned Irrelevance in Patients with First-Episode Schizophrenia-Spectrum Disorder
por: Ryan Sai-Ting Chu, et al.
Publicado: (2021)

Case Report: Cariprazine Efficacy in Young Patients Diagnosed With Schizophrenia With Predominantly Negative Symptoms
por: Octavian Vasiliu
Publicado: (2021)

Negative Symptoms of Schizophrenia: New Prospects of Cariprazine Treatment
por: Aleksandr M. Reznik, et al.
Publicado: (2020)

Adjunctive simvastatin treatment in schizophrenia patients; a double blind randomized and placebo controlled trial
por: Somaieh Ashrafi, et al.
Publicado: (2022)

Oxidative Stress Biomarkers as a Predictor of Stage Illness and Clinical Course of Schizophrenia
por: Dariusz Juchnowicz, et al.
Publicado: (2021)

Short-term functional outcome in psychotic patients: results of the Turku early psychosis study (TEPS)
por: Raimo K. R. Salokangas, et al.
Publicado: (2021)

Long-term outcomes of antipsychotic treatment in patients with first-episode schizophrenia: a systematic review
por: Karson C, et al.
Publicado: (2016)

Effectiveness of amisulpride in Chinese patients with predominantly negative symptoms of schizophrenia: a subanalysis of the ESCAPE study
por: Liang Y, et al.
Publicado: (2017)

Cariprazine in Three Acute Patients with Schizophrenia: A Real-World Experience
por: Montes JM, et al.
Publicado: (2021)

Influence of CFH gene on symptom severity of schizophrenia
por: Zhang C, et al.
Publicado: (2017)

Relationship between social and cognitive functions in people with schizophrenia
por: Tominaga T, et al.
Publicado: (2018)

Negative Symptoms in Schizophrenia: A Review and Clinical Guide for Recognition, Assessment, and Treatment
por: Correll CU, et al.
Publicado: (2020)

Cannabis-induced psychosis masquerading schizophrenia or vice-versa? A diagnostic dilemma
por: Rachit Sharma, et al.
Publicado: (2021)

Schizophrenia and sleep disorders: links, risks, and management challenges
por: Kaskie RE, et al.
Publicado: (2017)

Pictorial size perception in schizophrenia
por: Maria Lúcia de Bustamante Simas, et al.
Publicado: (2021)

Is There a Glutathione Centered Redox Dysregulation Subtype of Schizophrenia?
por: Lena Palaniyappan, et al.
Publicado: (2021)

Effect of Switching to Brexpiprazole on Plasma Homovanillic Acid Levels and Antipsychotic-Related Side Effects in Patients with Schizophrenia or Schizoaffective Disorder
por: Ichinose M, et al.
Publicado: (2021)

Online Left-Hemispheric In-Phase Frontoparietal Theta tACS for the Treatment of Negative Symptoms of Schizophrenia
por: Chuan-Chia Chang, et al.
Publicado: (2021)

Antipsychotic medication-mediated cognitive change in schizophrenia and polygenic score for cognitive ability
por: Rachael K. Blackman, et al.
Publicado: (2022)

Decline in Psychotic Symptoms in Addition to Cardiac and Metabolic Safety with Cariprazine After Poor Response to Previous Antipsychotic Treatments – A Series of Two Cases
por: Müller HHO, et al.
Publicado: (2021)

One patient with Sjogren’s syndrome presenting schizophrenia-like symptoms
por: Lin CE
Publicado: (2016)

Design and pilot evaluation of an evidence-based worksheet and clinician guide to facilitate nutrition counselling for patients with severe mental illness
por: Laura LaChance, et al.
Publicado: (2021)

Cognitive dysfunction and negative symptoms in patients with schizophrenia and their first-degree relatives from simplex and multiplex families
por: Zhang Z, et al.
Publicado: (2018)

Relationship Between Cognitive and Clinical Insight at Different Durations of Untreated Attentional Psychotic Symptoms in High-Risk Individuals
por: LiHua Xu, et al.
Publicado: (2021)

Intergeneration Transmission of Violence in Forensic Patients With a Diagnosis of Schizophrenia and Psychosis: Was Parental Alcoholic Abuse a Significant Factor?
por: Milena Petrovic, et al.
Publicado: (2021)

Global economic burden of schizophrenia: response to authors’ reply
por: Neil AL, et al.
Publicado: (2017)

Empathy and Its Relationship With Social Functioning in Individuals at Ultra-High Risk for Psychosis
por: Daan Jan Kuis, et al.
Publicado: (2021)

Clinical Validity of Subjective Clinical Prognosis in First Episode Psychosis Schizophrenia Patients: An Analysis of Data from the European First Episode Schizophrenia Trial (EUFEST) Study
por: Matei VP, et al.
Publicado: (2020)

Global economic burden of schizophrenia: letter in response
por: Neil AL, et al.
Publicado: (2016)

Neurocognition and Social Cognition— Possibilities for Diagnosis and Treatment in Ultra-High Risk for Psychosis State
por: Katarzyna Rek-Owodziń, et al.
Publicado: (2021)

Suicidality, self-stigma, social anxiety and personality traits in stabilized schizophrenia patients – a cross-sectional study
por: Vrbova K, et al.
Publicado: (2018)

The Effects of Recreation Therapy on the Habit of Smoking and Positive–Negative Symptoms Among Patients with Chronic Schizophrenia
por: Pirbalouti M. G., et al.
Publicado: (2017)

Repetitive transcranial magnetic stimulation as an adjunctive treatment for negative symptoms and cognitive impairment in patients with schizophrenia: a randomized, double-blind, sham-controlled trial
por: Zhuo K, et al.
Publicado: (2019)

Antipsychotics and risk of natural death in patients with schizophrenia
por: Chen Y, et al.
Publicado: (2019)

Metabolic disturbances in patients with paranoid schizophrenia treated with atypical antipsychotic drugs
por: Leonid Mikhaylovich Bardenshteyn, et al.
Publicado: (2010)